Susan Sharifi, MD
Neurology · Terre Haute, INNPI 1790896769
Payments from drug & device makers
Across 1,168 payments — averaging $119.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$34K
- Amgen$28K
- AbbVie$19K
- Lilly USA, LLC$18K
- Biohaven Pharmaceutical Holding Company Ltd.$12K
- Biohaven Pharmaceuticals, Inc.$5K
- plus $23K from 54 others
What the payments were for
- Consulting fees$3,5753%
- Speaking & faculty fees$105,96976%
- Travel & lodging$6,0344%
- Food & beverage$22,85016%
- Education$1,1541%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AJOVY$32,493
- AIMOVIG$27,370
- NURTEC ODT$16,681
- UBRELVY$16,389
- ZEMBRACE SYMTOUCH$2,854
- VNS Therapy$2,836
- ZAVZPRET$1,525
- Epidiolex$369
- Mavenclad$366
- Austedo XR$237
- Leqembi$230
- APOKYN$166
- VALTOCO$139
- MAYZENT$125
- Briviact$125
- ULTOMIRIS$125
- QUVIVIQ$123
- XCOPRI$123
- ZEPOSIA$122
- Symbravo$122
How this compares
$139,583 in reported general payments places this provider in the 85th percentile of 308 neurology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 271 | $410,118 |
| QuliptaAtogepant | 204 | $322,205 |
| UbrelvyUbrogepant | 146 | $237,715 |
| IngrezzaValbenazine Tosylate | 24 | $197,273 |
| Austedo XrDeutetrabenazine | 24 | $175,594 |
| AubagioTeriflunomide | 12 | $112,837 |
| AptiomEslicarbazepine Acetate | 33 | $112,536 |
| XcopriCenobamate | 50 | $75,764 |
| BriviactBrivaracetam | 42 | $75,444 |
| Topiramate ErTopiramate | 61 | $58,683 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 43 | $53,441 |
| Emgality PenGalcanezumab-Gnlm | 40 | $44,488 |
| ZavzpretZavegepant Hcl | 31 | $39,492 |
| Aimovig AutoinjectorErenumab-Aooe | 37 | $36,898 |
| FycompaPerampanel | 13 | $33,513 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieQulipta, Ubrelvy, Savella | $18,693 | $574,600367 claims |
| PfizerNurtec Odt, Zavzpret, Dilantin | $1,923 | $452,119315 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $250 | $197,27324 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $34,095 | $175,59424 claims |
| SanofiAubagio | $862 | $112,83712 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $168 | $112,53633 claims |
| SK Life Science, Inc.Xcopri | $572 | $75,76450 claims |
| UCB, Inc.Briviact | $779 | $75,44442 claims |
| Eisai Inc.Fycompa | $690 | $33,51313 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $128 | $31,02529 claims |
| Upsher-smith Laboratories LLCTopiramate | $146 | $3,187282 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 308 neurology providers in Indiana.
Other neurology in Terre Haute
- Adelle Maynard-WattsTerre Haute$81K
- Steven MaynardTerre Haute$77K
- Kristi GeorgeIndianapolis$10.8M
- Craig HerrmanIndianapolis$7.8M
- Martin FarlowIndianapolis$4.8M
- Jared BroschIndianapolis$4.7M
- Ajay GuptaFort Wayne$2.5M
- Christopher WilsonAvon$2M
- Alexandru BarboiIndianapolis$1.9M
- William ConteMerrillville$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.